The Law Offices of Frank R. Cruz announces an investigation of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. (“Hims”) and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims “has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization’ and are disseminating deceptive marketing that put patient safety at risk.”

On this news, Novo Nordisk’s stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Novo Nordisk securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,

2121 Avenue of the Stars, Suite 800,

Century City, California 90067

Call us at: 310-914-5007

Email us at: info@frankcruzlaw.com

Visit our website at: www.frankcruzlaw.com.

Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250624068913/en/